D. Hester

A phase I clinical trial of immunotherapy with interferon‐γ gene‐modified autologous melanoma cells

H. Seigler, D. Jolly, C. Weltz, 1997 .

Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA‐106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice

H. Seigler, C. Vervaert, Z. Abdel-wahab, 1998, Journal of surgical oncology.

Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity.

H. Seigler, P. Dematos, Z. Abdel-wahab, 1998, Cellular immunology.

Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.

H. Seigler, T. Darrow, J. Barber, 1996, Cellular immunology.

A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response.

H. Seigler, D. Jolly, C. Weltz, 1997, Cancer.

Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.

H. Seigler, S. Osanto, D. Jolly, 1997, Cancer gene therapy.